Prof Saul Faust, co-study leader at the University of Southampton and a consultant paediatrician, said: “These latest results show that this long-acting antibody is safe and could protect thousands of babies from hospitalisation when used in conditions similar to routine clinical practice. It is really important information for the UK to help decide on options for the future national RSV immunisation programme.”
Trending
- France's Dembélé named FIFA player of 2025, Spain's Bonmati scoops women's award
- Under-fire FIFA announces $60 World Cup tickets, for the few – DW – 12/17/2025
- Grangemouth chemicals plant to stay open after Government provides £120m funding
- EU rolls back 2035 internal combustion engine ban
- AI language models duped by poems – DW – 12/16/2025
- Series show: Emily trades Paris for La Dolce Vita in Rome
- Trump sues BBC for $10bn in lawsuit | US News
- "Islamic State propaganda is maybe more audible" in Syria among those who resent new authorities
